Within two years of reaching a milestone of 2,500 employees, SHL Group has reached 3,000 employees worldwide.
This increase is reflective of a steady yet rapid growth in the injectable drug delivery market and SHL’s effective commitment, productivity and management.
SHL offers innovative designs, robust manufacturing capabilities, a lean supply chain and strong partnerships.
With offices and manufacturing facilities in Taiwan, Sweden, US and China, SHL aims for the highest product and service quality, better brand recognition, and building of business values for employees and customers.
SHL has continuously invested in R&D and manufacturing capabilities, and currently houses more than 180 high precision moulding machines selected from leading brands such as Krauss Maffei, Engel and Netstal.
With expert engineers operating state-of-the-art equipment, SHL has been able to meet increasing customer demands for response time, quality and capacity.
SHL president Roger Samuelsson said: "SHL is committed to developing innovative devices and providing exceptional customer service, thus we never hesitate when it comes to further investments and expansions if it means providing better quality and capacity for our customers.
"We have been extending and expanding our services and production sites over the years, and will continue to do so to accommodate future needs.
"Reaching 3,000 employees in such a short time is a true milestone for us and we look forward to bringing more leading-edge technology to market in such areas as auto injectors and pen injectors, inhalers, connectivity and much more."
At present, SHL works with 80% of the world’s top 25 pharmaceutical companies and expands across Sweden, the US, Taiwan and China. There are currently nine major production sites in Taiwan.